These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The impact of systems approaches on biological problems in drug discovery. Hood L; Perlmutter RM Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453 [No Abstract] [Full Text] [Related]
3. Anticancer drug discovery and development. Colotta F Adv Exp Med Biol; 2008; 610():19-42. PubMed ID: 18593013 [No Abstract] [Full Text] [Related]
4. Perspective from the founding editors. Preface. Juliano R; Poste G; Tomlinson E Adv Drug Deliv Rev; 2013 Jan; 65(1):3-4. PubMed ID: 22940253 [No Abstract] [Full Text] [Related]
5. Looking forward in pharmaceutical process chemistry. Davies IW; Welch CJ Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417 [TBL] [Abstract][Full Text] [Related]
6. Fragment-based drug design: combining philosophy with technology. Bartoli S; Fincham CI; Fattori D Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. Timely synthetic support for medicinal chemists. Potoski J Drug Discov Today; 2005 Jan; 10(2):115-20. PubMed ID: 15718160 [TBL] [Abstract][Full Text] [Related]
9. Methods for the identification of vascular markers in health and disease: from the bench to the clinic. Roesli C; Neri D J Proteomics; 2010 Oct; 73(11):2219-29. PubMed ID: 20541635 [TBL] [Abstract][Full Text] [Related]
10. Use of high-content analysis for compound screening and target selection. Rausch O IDrugs; 2005 Jul; 8(7):573-7. PubMed ID: 15973566 [TBL] [Abstract][Full Text] [Related]
11. Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells. Keith WN; Thomson CM; Howcroft J; Maitland NJ; Shay JW Drug Discov Today; 2007 Aug; 12(15-16):611-21. PubMed ID: 17706542 [TBL] [Abstract][Full Text] [Related]
12. Drug-target residence time and its implications for lead optimization. Copeland RA; Pompliano DL; Meek TD Nat Rev Drug Discov; 2006 Sep; 5(9):730-9. PubMed ID: 16888652 [TBL] [Abstract][Full Text] [Related]
13. Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals. Pasquali I; Bettini R; Giordano F Adv Drug Deliv Rev; 2008 Feb; 60(3):399-410. PubMed ID: 17964684 [TBL] [Abstract][Full Text] [Related]
14. International Drug Discovery Science and Technology--BIT's Seventh Annual Congress. Bodovitz S IDrugs; 2010 Jan; 13(1):23-5. PubMed ID: 20024843 [TBL] [Abstract][Full Text] [Related]
15. Fragments, network biology and designing multiple ligands. Morphy R; Rankovic Z Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736 [TBL] [Abstract][Full Text] [Related]
16. Highlighting the new advances in drug discovery and development. Taliani S; Da Settimo F ChemMedChem; 2008 Jan; 3(1):181-4. PubMed ID: 18022978 [No Abstract] [Full Text] [Related]
17. Can cell systems biology rescue drug discovery? Butcher EC Nat Rev Drug Discov; 2005 Jun; 4(6):461-7. PubMed ID: 15915152 [TBL] [Abstract][Full Text] [Related]
18. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Zhao H Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735 [TBL] [Abstract][Full Text] [Related]
19. Chemical biology and drug design: three-dimensional, dynamic, and mechanistic nature of two multidisciplinary fields. Sawyer TK Chem Biol Drug Des; 2006 Mar; 67(3):196-200. PubMed ID: 16611212 [No Abstract] [Full Text] [Related]
20. Oral osmotically driven systems: 30 years of development and clinical use. Malaterre V; Ogorka J; Loggia N; Gurny R Eur J Pharm Biopharm; 2009 Nov; 73(3):311-23. PubMed ID: 19602438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]